Myricetin exerts anti-proliferative, anti-invasive, and pro-apoptotic effects on esophageal carcinoma EC9706 and KYSE30 cells via RSK2

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12583-12592

  Zang, Wenqiao ^a   Wang, Tao ^b   Wang, Yuanyuan ^b   Li, Min ^c   Xuan, Xiaoyan ^a   Ma, Yunyun ^a   Du, Yuwen ^a   Liu, Kangdong ^a   Dong, Ziming ^a   Zhao, Guoqiang ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HENAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Henan Medical College for Staff and Workers ^*

Author keywords

Esophageal carcinoma; Myricetin; RSK2

Indexed keywords

ANTINEOPLASTIC AGENT; MYRICETIN; PROTEIN BAD; PROTEIN MAD1; S6 KINASE; S6 KINASE 2; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; FLAVONOID; MAD1L1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN BINDING; RIBOSOMAL PROTEIN S6 KINASE, 90KDA, POLYPEPTIDE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINVASIVE ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PROTEIN BINDING; EC9706 CELL LINE; ESOPHAGEAL CANCER CELL LINE; ESOPHAGUS CARCINOMA; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; IN VITRO STUDY; KYSE30 CELL LINE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROAPOPTOTIC ACTIVITY; PROTEIN STRUCTURE; TUMOR INVASION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CARCINOMA; CELL CYCLE; CELL MOTION; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ESOPHAGUS TUMOR; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROTEIN DOMAIN; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CARCINOMA; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLAVONOIDS; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925284087     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2579-4     Document Type: Article

References (35)

1. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases withdiverse biological functions. Microbiol Mol Biol Rev. 2004;68:320–44.
2. Jones SW, Erikson E, Blenis J, Maller JL, Erikson RL. A Xenopus ribosomal protein S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases. Proc Natl Acad Sci U S A. 1988;85:3377–81.
3. Frodin M, Jensen CJ, Merienne K, Gammeltoft S A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates (2000) PDK1. EMBO J 19:2924–2934.
4. Artamonov M, Momotani K, Utepbergenov D, Franke A, Khromov A, Derewenda ZS. The p90 ribosomal S6 kinase (RSK) is a mediator of smooth muscle contractility. PLoS One. 2013;8(3):e58703.
5. Nebreda AR, Gavin AC. Perspectives: signal transduction. Cell survival demands some RSK Science. 1999;286:1309–10.
6. Redman EK, Brookes PS, Karcz MK. Role of p90 (RSK) in regulating the Crabtree effect: implications for cancer. Biochem. Soc Trans. 2013;41(1):124–6.
7. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24:21–44.
8. Rubinfeld H, Seger R. The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol. 2005;31:151–74.
9. Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs. 2009;18(12):1893–905.
10. Meyuhas O. Physiological roles of ribosomal protein S6: one of its kinds. Int Rev Cell Mol Biol. 2008;268:1–37.
11. Cho YY, Yao K, Kim HG, Kang BS, Zheng D, Bode AM. Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res. 2007;Cancer Res 67:8104–12.
12. Weng CJ, Yen GC. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastasis Rev. 2012;31(1–2):323–51.
13. López-Lázaro M, Willmore E, Austin CA. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutat Res. 2010;696(1):41–7.
14. Nirmala P, Ramanathan M. Effect of myricetin on 1, 2 dimethylhydrazine induced rat colon carcinogenesis. J Exp Ther Oncol. 2011;9(2):101–8.
15. Sun F, Zheng XY, Ye J, Wu TT, Jl W, Chen W. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer. 2012;64(4):599–606.
16. Jung SK, Lee KW, Byun S, Kang NJ, Lim SH, et al. Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res. 2008;68(14):6021–9.
17. Rodgers EH, Grant MH. The effect of the flavonoids, quercetin, myricetin and epicatechin on the growth and enzyme activities of MCF7 human breast cancer cells. Chem Biol Interact. 1998;116(3):213–28.
18. Kuntz S, Wenzel U, Daniel H. Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur J Nutr. 1999;38(3):133–42.
19. Maggiolini M, Recchia AG, Bonofiglio D, Catalano S, Vivacqua A, Carpino A. The red wine phenolics piceatannol and myricetin act as agonists for estrogen receptor alpha in human breast cancer cells. J Mol Endocrinol. 2005.
20. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9(10):747–58.
21. RJ S, Bates PA, Waelkens E, Dallman M, Lamb J. A siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis. Oncogene. 2011;30:3513–21.
22. Gawecka JE, Young-Robbins SS, Sulzmaier FJ, Caliva MJ, Heikkilä MM, Matter ML. RSK2 protein suppresses integrin activation and fibronectin matrix assembly and promotes cell migration. J Biol Chem. 2012;287(52):43424–37.
23. van Jaarsveld MT, Blijdorp IC, Boersma AW, Pothof J, Mathijssen RH, Verweij J. The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin. Eur J Cancer. 2013;49(2):345–51.
24. Eisinger-Mathason TS, Andrade J, Lannigan DA. RSK in tumorigenesis: connections to steroid signaling. Steroids. 2010;75(3):191–202.
25. Hilinski MK, Mrozowski RM, Clark DE, Lannigan DA. Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability. Bioorg Med Chem Lett. 2012;22(9):3244–7.
26. Lu W, Liu X, Cao X, Xue M, Liu K, Zhao Z. hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration. J Med Chem. 2011;54:3564–74.
27. Peng C, Zhu F, Wen W, Yao K, Li S, Zykova T. Tumor necrosis factor receptor-associated factor family protein 2 is a key mediator of the epidermal growth factor-induced ribosomal S6 kinase 2/cAMP-responsive element-binding protein/Fos protein signaling pathway. J Biol Chem. 2012;287(31):25881–92.
28. Malakhova M, Kurinov I, Liu K, Zheng D, D'Angelo I, Shim JH. Structural diversity of the active N-terminal kinase domain of p90 ribosomal S6 kinase 2. PLoS One. 2009;4(11):e8044.
29. Shimura Y, Kuroda J, Ri M, Nagoshi H, Yamamoto-Sugitani M, Kobayashi T. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. Mol Cancer Ther. 2012;11(12):2600–9.
30. Utepbergenov D, Derewenda U, Olekhnovich N, Szukalska G, Banerjee B, et al. Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL010 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor. Biochemistry. 2012;51(33):6499–510.
31. Rottmann S, Lüscher B. The Mad side of the Max network: antagonizing the function of Myc and more. Curr Top Microbiol Immunol. 2006;302:63–122.
32. Vigneron S, Brioudes E, Burgess A, Labbé JC, Lorca T, Castro A. RSK2 is a kinetochore-associated protein that participates in the spindle assembly checkpoint. Oncogene. 2010;29(24):3566–74.
33. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999;286(5443):1358–62.
34. Virdee KS, Parone PA, Tolkovsky AM. Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contribute to cell survival. Curr Biol. 2000;10:1151–4.
35. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999;286(5443):1358–62.